The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.

Immune cells work to fight infection and other diseases. Different subsets work together to elicit a healthy immune response; ...

A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies. T cell-based ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

Bicistronic CD19/CD22-directed CAR-T cell therapy achieved high remission rates and durable responses in pediatric B-ALL patients. One-year EFS and OS rates were 75.5% and 93.5%, respectively, with ...

Glioblastoma (GBM), an aggressive form of cancer that grows in the brain or spinal cord, occurs at an incidence rate of about 3/100,000 persons in the United States. Effective treatments remain ...

ALLO-316 targets CD70, a surface antigen highly expressed in renal cell carcinoma, offering potential for heavily pretreated patients. The FDA's designation is based on early evidence from the phase 1 ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

The study, "A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans,” was published in Immunity. “Our study ...